
Christopher Weil & Company
11236 El Camino Real, Suite 200, San Diego, CA, 92130, United States
Overview
Christopher Weil & Company is a San Diego-based financial services firm. CWC has developed a Business Continuity Plan on how they will respond to events that significantly disrupt their business. Since the timing and impact of disasters and disruptions are unpredictable, they will have to be flexible in responding to actual events as they occur. It was founded in 1988 and is headquartered in San Diego, California.
- Total investments
- 2
- Lead investments
- 0
- Investments · 12mo
- 0
- Active investors
- 2
Sector focus
- Commercial Real Estate
- Finance
- Financial Services
- Real Estate
- Real Estate Investment
- Residential
Investment portfolio
- Vessix Vascular
Participated · Series B · Aug 2011
Vessix Vascular (formerly Minnow Medical) is a Laguna Hills, California–based developer of percutaneous radiofrequency balloon catheter technology. Its initial product, the ZCath System, holds a CE Mark for reducing plaque in peripheral leg arteries. Founded in 2003 and led by CEO Raymond W. Cohen, the company is focused on advancing its RF balloon catheter platform. Vessix established a European subsidiary in Paris to support planned European clinical studies and anticipated commercial launches. The company intends to use recent funding to accelerate product development and to conduct multi-center clinical trials to expand indications. It completed a $23M Series B to fund those efforts. Minnow Medical is a Laguna Hills, California-based developer of a platform technology employing radiofrequency thermoplasty to treat in-stent restenosis and other peripheral vascular conditions. Its core product is the ZCath™ System, a patented angioplasty balloon catheter that delivers controlled radiofrequency energy intended to reverse restenosis in peripheral vascular stents. The company closed two financing transactions totaling $4.7M — $3.2M in preferred stock and $1.5M in convertible notes that convert into preferred stock. Proceeds will be used to extinguish bank debt, provide working capital and finance a European clinical trial to further test the ZCath System. The financings were led by Neomed Management with participation from Minnow Board Chairman Olav Bergheim, Christopher Weil and Company, Inc. and other private investors. The company is advancing clinical validation of its technology while addressing near-term financing needs.
Team
Laura Gordon
CFO
John V. Wells
Chief Investment Officer
LinkedIn